Data from clinical trials investigating treatments for pulmonary hypertension and pulmonary fibrosis will be highlighted at ATS 2026.
RT’s Three Key Takeaways:
- Pivotal Trial Data: United Therapeutics will present efficacy and safety results from the TETON-1 and TETON-2 phase 3 studies evaluating inhaled treprostinil for idiopathic pulmonary fibrosis (IPF).
- Pulmonary Hypertension Research: The ADVANCE OUTCOMES study of ralinepag and the ARTISAN study of parenteral treprostinil will provide new insights into managing pulmonary arterial hypertension (PAH).
- Expanded Clinical Insights: New research from the PHINDER and TETON-PPF studies will examine patient outcomes and diagnostic accuracy in interstitial lung disease (ILD) and progressive pulmonary fibrosis (PPF).
United Therapeutics Corp announced it will present 12 new data sets across its commercial and development portfolio at the ATS 2026.
The presentations include results from the TETON phase 3 pivotal studies of inhaled treprostinil in IPF. These sessions will cover efficacy and safety results from TETON-1, as well as integrated data from both TETON-1 and TETON-2.
The company will also share results from the ADVANCE OUTCOMES study of ralinepag for the treatment of PAH. Additional PAH-focused research includes an interim analysis from the ARTISAN study, which evaluates how early treatment with high-dose parenteral treprostinil reduces mean pulmonary artery pressure and improves risk status.
Other research includes an interim analysis from the TETON-PPF study regarding inhaled treprostinil in PPF and preliminary results from the PHINDER study. The PHINDER study examines patients with ILD with and without pulmonary hypertension (PH), focusing on clinician suspicion accuracy and patient-reported outcomes.
“We are thrilled to share additional positive data from the TETON-1 study in IPF and the ADVANCE OUTCOMES study in PAH, our pivotal studies that achieved unprecedented results in these two life-threatening diseases that have significant unmet needs,” said Andrew Nelsen, vice president, global medical affairs at United Therapeutics, in a news release.
According to Nelsen, the data from research programs in pulmonary hypertension and ILD, including PHINDER, ARTISAN, and TETON-PPF, will provide clinical insights that may impact how these diseases are managed and help improve outcomes for patients.
Additional poster presentations will cover real-world dosing of parenteral treprostinil, patient insights into subcutaneous pump therapy, and real-world persistence to oral treprostinil in patients with PAH over the last decade. The company will also present a subgroup analysis of the EXPEDITE study focusing on clinical outcomes for patients with methamphetamine-associated PAH treated with parenteral induction therapy.
